# US 8,278,084 B2 · Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,084 B2
- Document ID: US8278084B2
- Status: Granted
- Kind: B2
- Application number: 12/704,205
- Filed: 2010-02-11
- Published: 2010-08-12
- Granted: 2012-10-02
- Earliest claimed: 2009-02-11
- Assignees: Northwestern University
- Inventors: Richard B. Silverman; Fengtian Xue
- Web page: https://patentgrep.com/patent/US8278084B2

## CPC

- C07D 401/10: linked by a carbon chain containing aromatic rings
- A61P 39/06: Free radical scavengers or antioxidants
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.

## Claims

### Claim 1

A nitric oxide synthase inhibitor compound of a formula
wherein each said X and each said Y is independently selected from CH and N, providing one of said X and Y in each said pair of X and Y is N; and Ar is selected from divalent aryl and heteroaryl linker moieties, and a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 where each of said Y is N.

### Claim 3 (depends on 1)

The compound of claim 1 wherein Ar is selected from naphthyl, substituted naphthyl, phenyl, substituted phenyl, pyridinyl and substituted pyridinyl linker moieties.

### Claim 4 (depends on 3)

The compound of claim 3 wherein Ar is selected from phenyl, substituted phenyl, pyridinyl and substituted pyridinyl linker moieties.

### Claim 5 (depends on 4)

The compound of claim 4 wherein said terminal amino-substituted ring moieties have a meta-linkage to said Ar moiety.

### Claim 6 (depends on 5)

The compound of claim 5 where Ar is selected from phenyl and pyridinyl moieties.

### Claim 7 (depends on 5)

The compound of claim 5 wherein each of said Y is N.

### Claim 8 (depends on 1)

The compound of claim 1 wherein said compound is an ammonium salt.

### Claim 9 (depends on 8)

The compound of claim 8 wherein said salt has a counter ion that is conjugate base of a protic acid.

### Claim 10 (depends on 1)

The compound of claim 1 complexed with a nitric oxide synthase enzyme.

### Claim 11

A nitric oxide synthase inhibitor compound of a formula
wherein X and Y are independently selected from CH and N, providing at least one of X and Y is CH; and Z1 and Z2 are independently selected from CH and N, providing one of Z1 and Z2 is N; and a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The compound of claim 11 wherein X is CH.

### Claim 13 (depends on 12)

The compound of claim 12 wherein Y is N.

### Claim 14 (depends on 11)

The compound of claim 11 wherein said amino-substituted terminal ring moieties have a meta-linkage.

### Claim 15 (depends on 1)

The compound of claim 1 wherein said compound is an ammonium salt.

### Claim 16 (depends on 1)

The compound of claim 1 complexed with a nitric oxide synthase enzyme.

### Claim 17

A method of inhibiting a nitric oxide synthase comprising contacting a nitric oxide synthase with an effective amount of a compound of a formula
wherein each said X and each said Y is independently selected from CH and N, providing one of said X and Y in each said pair of X and Y is N; and Ar is selected from divalent aryl and heteroaryl linker moieties, and a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17 wherein Ar is selected from phenyl, substituted phenyl, pyridinyl and substituted pyridinyl linker moieties.

### Claim 19 (depends on 18)

The method of claim 18 wherein Ar is selected from phenyl and pyridinyl moieties.

### Claim 20 (depends on 19)

The method of claim 19 wherein said amino-substituted terminal ring moieties have a meta-linkage to said Ar moiety, said method selective for inhibition of neuronal nitric oxide synthase.
